Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Proactively manage your pharmacy inventory
Manage your formulary budget
Anticipate generic drug launch
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Method of synthesis of 1,3-dioxolane nucleosides|
|Abstract:||A synthesis of 1,3-dioxolane nucleosides that includes condensing a 2-0-protected-5-0-acylated-1,3-dioxolane with a purine or pyrimidine base in the presence of a titanium containing Lewis acid to provide predominately the desired .beta.-isomer in the C1'-position of a 1,3-dioxolane nucleoside. A process for the resolution of a racemic mixture of 1,3-dioxolane nucleoside enantiomers is also disclosed that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers.|
|Inventor(s):||Liotta; Dennis C. (Stone Mountain, GA)|
|Assignee:||Emory University (Atlanta, GA)|
|Filing Date:||Dec 06, 1991|
|Claims:||1. A process for the preparation of 1,3-dioxolane nucleosides comprising reacting a 2-0-protected-5-0-acylated-1,3-dioxolane with an oxygen or nitrogen protected purine or pyrimidine base in the presence of a titanium catalyst of the formula: |
wherein m=4; n=2, 3, or 4; Ti=titanium; X=Cl, Br, or I; and Y is alkoxy, amino, alkylamino, dialkylamino, arylamino, diarylamino, alkylarylamino, and mixtures thereof, or a bifunctional molecule that contains both an alkoxy and an amino bifunctional group and that is bound to the titanium molecule by both the alkoxy and amino moieties, to provide predominately the desired .beta.-isomer in the C1'-position of the 1,3-dioxolane nucleoside.
2. The method of claim 1, wherein the titanium catalyst is selected from the group consisting of TiCl.sub.4, TiCl.sub.2 (OiPr).sub.2, and TiCl.sub.3 (OiPr).
3. The method of claim 1, wherein the 1,3-dioxolane nucleoside is 2-hydroxymethyl-5-(thymidin-1-yl)-1,3-dioxolane.
4. The method of claim 1, wherein the purine of pyrimidine base is selected form the group consisting of cytosine, thymine, uracil, adenine, and guanine.
5. The method of claim 1, wherein the alkoxy group is lower alkoxy (C.sub.5 or less).
6. The method of claim 1, wherein the alkyl moiety in the alkylamino group has one to five carbon atoms.
7. The method of claim 1, wherein the bifunctional molecule is selected from the group consisting of 2-aminoethanol, 3-aminopropanol, and 1-substituted and 2-substituted derivatives thereof in which the substituents are lower alkyl (C.sub.5 or less) or aryl groups.
8. The method of claim 1, wherein the titanium catalyst is TiCl.sub.4.
9. The method of claim 1, wherein the alkyl group contains one to five carbon atoms.
10. The method of claim 1, wherein the 1,3-dioxolane nucleoside is 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-dioxolane.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.